NEW: Premarket Now Starts at 4AM!

We’re excited to announce the extension of premarket and aftermarket hours! Our members now have access to quotes daily from 4:00 AM to 8:00 PM ET — offering greater flexibility and deeper insights into market trends beyond regular trading hours.

Upgrade to FINVIZ*Elite to access premarket quotes »

Last Close
Apr 17 04:00PM ET
5.77
Dollar change
+0.31
Percentage change
5.68
%
IndexRUT P/E- EPS (ttm)-1.54 Insider Own1.20% Shs Outstand75.37M Perf Week12.26%
Market Cap434.88M Forward P/E- EPS next Y-1.77 Insider Trans-6.90% Shs Float74.09M Perf Month-13.88%
Income-108.70M PEG- EPS next Q-0.37 Inst Own49.60% Short Float15.30% Perf Quarter-11.37%
Sales- P/S- EPS this Y36.90% Inst Trans-17.91% Short Ratio5.75 Perf Half Y-2.45%
Book/sh3.21 P/B1.80 EPS next Y-10.44% ROA-50.90% Short Interest11.34M Perf Year-41.60%
Cash/sh3.63 P/C1.59 EPS next 5Y- ROE-68.00% 52W Range4.70 - 10.44 Perf YTD-17.10%
Dividend Est.- P/FCF- EPS past 5Y10.40% ROI- 52W High-44.71% Beta2.79
Dividend TTM- Quick Ratio7.00 Sales past 5Y- Gross Margin- 52W Low22.77% ATR (14)0.54
Dividend Ex-Date- Current Ratio7.20 EPS Y/Y TTM-51.01% Oper. Margin- RSI (14)47.34 Volatility7.42% 9.05%
Employees74 Debt/Eq0.09 Sales Y/Y TTM- Profit Margin- Recom- Target Price24.00
Option/ShortYes / Yes LT Debt/Eq0.09 EPS Q/Q30.30% Payout- Rel Volume0.59 Prev Close5.46
Sales Surprise- EPS Surprise-39.93% Sales Q/Q- EarningsMar 06 BMO Avg Volume1.97M Price5.77
SMA20-1.29% SMA50-13.75% SMA200-16.34% Trades Volume1,166,483 Change5.68%
Date Action Analyst Rating Change Price Target Change
Jan-28-25Initiated Evercore ISI Outperform $23
Dec-20-24Initiated Chardan Capital Markets Buy $20
Oct-14-24Resumed Leerink Partners Outperform $20
Jul-24-24Initiated ROTH MKM Buy $36
May-29-24Initiated Robert W. Baird Outperform $27
Apr-15-24Initiated Leerink Partners Outperform $20
Dec-05-23Initiated Canaccord Genuity Buy $9
Dec-09-22Resumed ROTH Capital Buy $25
Nov-16-22Initiated RBC Capital Mkts Outperform $5
Aug-26-22Initiated Oppenheimer Outperform $3.50
Apr-15-25 07:00AM
Mar-24-25 04:01PM
Mar-22-25 10:30AM
Mar-21-25 11:50AM
Mar-17-25 07:00AM
11:40AM Loading…
Mar-14-25 11:40AM
Mar-06-25 07:00AM
Mar-04-25 07:00AM
Feb-28-25 11:30AM
Feb-20-25 07:00AM
Feb-13-25 04:14PM
Feb-12-25 01:25PM
Feb-04-25 07:00AM
Jan-31-25 07:20AM
Jan-30-25 07:00AM
10:48AM Loading…
Jan-20-25 10:48AM
Dec-19-24 07:00AM
Dec-16-24 07:00AM
Dec-11-24 07:00AM
Dec-05-24 07:00AM
Dec-03-24 07:00AM
Dec-02-24 07:00AM
Nov-18-24 07:00AM
Nov-13-24 07:00AM
Nov-07-24 04:01PM
Oct-24-24 07:00AM
Oct-12-24 06:05PM
Sep-09-24 04:01PM
Sep-04-24 07:00AM
Aug-13-24 07:00AM
09:02PM Loading…
Aug-12-24 09:02PM
Aug-09-24 08:44AM
06:00AM
Aug-06-24 04:01PM
07:00AM
Jul-29-24 07:00AM
Jul-17-24 07:00AM
Jul-06-24 07:21AM
Jul-04-24 02:13PM
Jun-28-24 07:00AM
Jun-21-24 07:00AM
Jun-20-24 07:00AM
Jun-18-24 12:31PM
Jun-14-24 09:40AM
Jun-05-24 11:42AM
May-29-24 09:40AM
May-28-24 07:00AM
May-23-24 03:41PM
May-18-24 09:32AM
May-10-24 11:00AM
May-09-24 04:01PM
08:00AM
06:49AM
May-08-24 09:00PM
04:01PM
May-04-24 08:00AM
May-02-24 07:00AM
Apr-25-24 07:00AM
Apr-08-24 06:59AM
Apr-02-24 07:00AM
Apr-01-24 05:00PM
Mar-19-24 08:00AM
Mar-11-24 07:00AM
Mar-10-24 11:10AM
Mar-08-24 10:46AM
07:00AM
Mar-07-24 07:13AM
06:00AM
Mar-01-24 09:00AM
Feb-28-24 07:05AM
Feb-22-24 07:00AM
Feb-07-24 07:00AM
Jan-24-24 09:00AM
Jan-08-24 12:27PM
07:45AM
Dec-17-23 05:49PM
Dec-14-23 07:30AM
Dec-11-23 12:19PM
Nov-02-23 04:01PM
Oct-30-23 12:11PM
Oct-26-23 07:30AM
Oct-24-23 07:30AM
Oct-03-23 07:30AM
Sep-14-23 07:30AM
Sep-12-23 07:30AM
Aug-28-23 07:30AM
Aug-14-23 07:30AM
Aug-03-23 04:01PM
07:30AM
Jul-31-23 08:30AM
Jun-22-23 08:42AM
08:30AM
Jun-21-23 12:08PM
Jun-20-23 08:30AM
Jun-15-23 04:23PM
10:45AM
Jun-09-23 09:00AM
Jun-08-23 11:30AM
Jun-07-23 08:07AM
08:00AM
Mind Medicine (MindMed) Inc., a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders. The company's lead product candidates include MM120, which is in phase 3 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder; and MM402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase I clinical trials for the treatment of core symptoms of autism spectrum disorder. Mind Medicine (MindMed) Inc. is headquartered in New York, New York.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Barrow RobertChief Executive OfficerMar 25 '25Sale6.7421,208142,942856,556Mar 26 05:00 PM
Karlin DanielChief Medical OfficerMar 25 '25Sale6.746,83646,075446,177Mar 26 05:00 PM
Sullivan MarkChief Legal OfficerMar 25 '25Sale6.746,57644,322316,621Mar 26 05:00 PM
Liao CarrieChief Accounting OfficerMar 25 '25Sale6.742,34715,819144,923Mar 26 05:00 PM
MARK SULLIVANOfficerMar 25 '25Proposed Sale6.746,57644,304Mar 25 04:11 PM
CARRIE LIAOOfficerMar 25 '25Proposed Sale6.742,34715,812Mar 25 04:09 PM
ROBERT B BARROWOfficerMar 25 '25Proposed Sale6.7421,208142,883Mar 25 04:06 PM
DANIEL ROLLINGS KARLINOfficerMar 25 '25Proposed Sale6.746,83646,056Mar 25 04:03 PM
Barrow RobertChief Executive OfficerDec 26 '24Sale7.4319,106141,958526,666Dec 27 04:31 PM
Liao CarrieChief Accounting OfficerDec 26 '24Sale7.432,27316,88897,270Dec 27 04:31 PM
Karlin DanChief Medical OfficerDec 26 '24Sale7.436,64349,357338,013Dec 27 04:30 PM
Sullivan MarkChief Legal OfficerDec 26 '24Sale7.434,51933,576173,197Dec 27 04:30 PM
ROBERT B BARROWOfficerDec 26 '24Proposed Sale7.4319,106141,979Dec 26 04:39 PM
MARK SULLIVANOfficerDec 26 '24Proposed Sale7.434,51933,581Dec 26 04:31 PM
DAN ROLLINGS KARLINOfficerDec 26 '24Proposed Sale7.436,64349,365Dec 26 04:30 PM
CARRIE LIAOOfficerDec 26 '24Proposed Sale7.432,27316,891Dec 26 04:28 PM
GRYSKA DAVID WDirectorDec 05 '24Buy7.172,50017,92519,851Dec 05 04:30 PM
Sullivan, MarkOfficerSep 25 '24Proposed Sale5.984,43026,487Sep 25 08:31 PM
Liao CarrieChief Accounting OfficerSep 25 '24Sale5.982,35214,06599,543Sep 25 08:30 PM
Barrow RobertChief Executive OfficerSep 25 '24Sale5.9819,771118,231545,772Sep 25 08:29 PM
Karlin, DanOfficerSep 25 '24Proposed Sale5.986,87141,081Sep 25 08:29 PM
Karlin DanChief Medical OfficerSep 25 '24Sale5.986,87141,089344,656Sep 25 08:29 PM
Sullivan MarkChief Legal OfficerSep 25 '24Sale5.984,43026,491177,716Sep 25 08:28 PM
Barrow, RobertOfficer, DirectorSep 25 '24Proposed Sale5.9819,771118,210Sep 25 08:27 PM
GRYSKA DAVID WDirectorAug 23 '24Buy5.983,50020,93017,351Aug 26 07:00 PM
Halperin Wernli MiriExecutive PresidentAug 21 '24Option Exercise3.7050,000185,000235,000Aug 22 04:30 PM
Barrow RobertChief Executive OfficerAug 19 '24Buy6.315003,155565,043Aug 20 09:14 PM
Barrow RobertChief Executive OfficerAug 20 '24Buy6.125003,060565,543Aug 20 09:14 PM
Karlin DanChief Medical OfficerJun 25 '24Sale7.226,92549,998351,527Jun 25 07:00 PM
Sullivan MarkChief Legal OfficerJun 25 '24Sale7.2217,854128,906182,146Jun 25 07:00 PM
Barrow RobertChief Executive OfficerJun 25 '24Sale7.2215,659113,058564,543Jun 25 07:00 PM